



Universiteit  
Leiden  
The Netherlands

## **Novel approaches in clinical development of cannabinoid drugs**

Klumpers, L.E.

### **Citation**

Klumpers, L. E. (2014, January 21). *Novel approaches in clinical development of cannabinoid drugs*. Retrieved from <https://hdl.handle.net/1887/23050>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/23050>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/23050> holds various files of this Leiden University dissertation

**Author:** Klumpers, Linda

**Title:** Novel approaches in clinical development of cannabinoid drugs

**Issue Date:** 2014-01-21

**NOVEL APPROACHES IN CLINICAL DEVELOPMENT OF CANNABINOID DRUGS**



## Promotiecommissie

### PROMOTORES

**Prof. dr. J. M. A. van Gerven**

*Professor of Clinical Neuropsychopharmacology, Leiden University Medical Center and Centre for Human Drug Research*

**Prof. dr. A. F. Cohen**

*Professor of Clinical Pharmacology, Leiden University Medical Center and Centre for Human Drug Research*

### OVERIGE LEDEN

**Prof. dr. P. H. van der Graaf**

*Professor of Bio-pharmaceutical Sciences, Leiden University*

**Dr. J. T. Tamsma**

*Internist and Medical Director of the Leiden University Medical Center*

**Prof. dr. R. F. Witkamp**

*Professor of Nutrition and Pharmacology, Wageningen University*

### DESIGN

Caroline de Lint, Voorburg (caro@delint.nl)

### ACKNOWLEDGEMENTS

The publication of this thesis was financially supported by the foundation Centre for Human Drug Research, Leiden

<b>CHAPTER I</b>	7
Introduction to the endocannabinoid system as a target for drug development	
<b>CHAPTER II</b>	49
Novel $\Delta^9$ -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects	
<b>CHAPTER III</b>	79
Manipulating brain connectivity with $\Delta^9$ -tetrahydrocannabinol: a pharmacological resting state fMRI study	
<b>CHAPTER IV</b>	115
Surinabant, a selective CB <sub>1</sub> antagonist, inhibits THC-induced central nervous system and heart rate effects in humans	
<b>CHAPTER V</b>	145
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects	
<b>CHAPTER VI</b>	177
Pharmacokinetic/pharmacodynamic modelling and simulation of the effects of different CB <sub>1</sub> antagonists on $\Delta^9$ -tetrahydrocannabinol challenge tests in healthy volunteers	
<b>CHAPTER VII</b>	203
General discussion	
<b>NEDERLANDSE SAMENVATTING / SUMMARY IN DUTCH</b>	215
<b>CURRICULUM VITAE</b>	229
<b>ACKNOWLEDGEMENTS</b>	231
<b>PUBLICATION LIST</b>	232